PROTECT-1 Study Demonstrated Efficacy of the Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Treatment of Patients with Moderate to Severe Crohn's Disease

Similar Items

• PROTECT-1 Maintenance Phase Study Results demonstrate efficacy of the Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Crohn's Disease
  by: Bekker, P, et al.
  Published: (2009)
• Traficet-EN (CCX282-B), an orally active inhibitor of chemokine receptor CCR9, for treatment of Crohn's disease
  by: Bekker, P, et al.
  Published: (2007)
• PROTECT-1: A prospective randomized trial of CCX282-B (Traficet-EN), a novel oral therapy targeting chemokine receptor 9 in Crohn's disease
  by: Keshav, S, et al.
  Published: (2007)
• Protect-1, a prospective randomized oral therapy evaluation of CCX282-B (Traficet-EN) in Crohn's disease trial
  by: Bekker, P, et al.
  Published: (2008)
• Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease.
  by: Walters, M, et al.
  Published: (2010)